About BeyondSpring (NASDAQ:BYSI)
BeyondSpring Inc. is a global clinical-stage biopharmaceutical company. The Company is focused on the development of cancer therapies. The Company is engaged in advancing its lead product, Plinabulin, into a Phase II/III clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase II/III clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase III clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer (NSCLC). Plinabulin has also entered in a Phase I/II clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab. The Company's BPI-002 program is based on an oral small molecule agent, which induces T-cell activation. The Company's IkappaB kinase (IKK) program, BPI-003, is based on a small molecule inhibitor of IKK, a protein kinase.
Industry, Sector and Symbol:
- Industry: Biotechnology & Medical Research
- Sub-Industry: N/A
- Sector: Medical
- Symbol: NASDAQ:BYSI
- CUSIP: N/A
- Web: www.beyondspringpharma.com
- Current Ratio: 14.02%
- Quick Ratio: 14.02%
Sales & Book Value:
- Annual Sales: N/A
- Price / Sales: N/A
- Book Value: $1.77 per share
- Price / Book: 19.92
- Employees: 25
- Outstanding Shares: 22,840,000
Frequently Asked Questions for BeyondSpring (NASDAQ:BYSI)
What is BeyondSpring's stock symbol?
BeyondSpring trades on the NASDAQ under the ticker symbol "BYSI."
How were BeyondSpring's earnings last quarter?
BeyondSpring Inc. (NASDAQ:BYSI) posted its quarterly earnings results on Thursday, November, 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.69) by $0.01. View BeyondSpring's Earnings History.
When will BeyondSpring make its next earnings announcement?
Where is BeyondSpring's stock going? Where will BeyondSpring's stock price be in 2017?
3 Wall Street analysts have issued twelve-month price targets for BeyondSpring's stock. Their forecasts range from $50.00 to $60.00. On average, they expect BeyondSpring's share price to reach $54.00 in the next twelve months. View Analyst Ratings for BeyondSpring.
What are Wall Street analysts saying about BeyondSpring stock?
Here are some recent quotes from research analysts about BeyondSpring stock:
- 1. According to Zacks Investment Research, "BeyondSpring Inc. is a clinical stage biopharmaceutical company. It focused on the development of cancer therapies. The Company's lead product consists of into a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer and a Phase 2/3 clinical trial in the prevention of chemotherapy-induced Neutropenia. BeyondSpring Inc. is based in New York, United States. " (11/13/2017)
- 2. Maxim Group analysts commented, "BeyondSpring announced that the enrollment of the first patient in China for Plinabulin (P2/3 trial) in the Harbin Medical University Cancer Hospital in Harbin, China. This news follows other recent positives which include: ○ Positive Regulatory Reforms in China. The State Council of China announced on October 8, 2017 regulatory reforms, which could translate into an accelerated review (shorter time to the marketplace). Our current timeline assumes approvals and launch in China by 2020. This news is consistent with what we are hearing amongst our other covered companies in China such as BeiGene (BGNE – $80.01 – Buy). ○ Two China-based Grants. The first from the city government of Dalian, China. The second from the Dalian Economic Development Park. Conclusion: Plinabulin could become the standard of care for chemo patients as a prophylactic treatment for the CIN indication alone. The market opportunity extends beyond the $8B biologics market and could be upwards of $30B." (10/27/2017)
Who are some of BeyondSpring's key competitors?
Some companies that are related to BeyondSpring include Intrexon Corporation (XON), Genus plc (GNS), Medpace Holdings (MEDP), Esperion Therapeutics (ESPR), Editas Medicine (EDIT), Momenta Pharmaceuticals (MNTA), Arena Pharmaceuticals (ARNA), Genomic Health (GHDX), Albany Molecular Research (AMRI), Enanta Pharmaceuticals (ENTA), BIOHAVEN PHARM (BHVN), WAVE Life Sciences (WVE), Heron Therapeutics (HRTX), Cellectis S.A. (CLLS), ImmunoGen (IMGN), CRISPR THERAPTC (CRSP), ANI Pharmaceuticals (ANIP) and Abeona Therapeutics (ABEO).
When did BeyondSpring IPO?
(BYSI) raised $4 million in an initial public offering (IPO) on Thursday, March 9th 2017. The company issued 200,000 shares at $20.00 per share. Rodman & Renshaw (a Unit of H.C. Wainwright & Co.) served as the underwriter for the IPO.
How do I buy BeyondSpring stock?
Shares of BeyondSpring can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BeyondSpring's stock price today?
One share of BeyondSpring stock can currently be purchased for approximately $35.25.
How big of a company is BeyondSpring?
BeyondSpring has a market capitalization of $805.29 million. BeyondSpring employs 25 workers across the globe.
How can I contact BeyondSpring?
BeyondSpring's mailing address is 28 LIBERTY STREET 39TH FLOOR, NEW YORK NY, 10005. The company can be reached via phone at 646-528-4184 or via email at [email protected]
MarketBeat Community Rating for BeyondSpring (NASDAQ BYSI)MarketBeat's community ratings are surveys of what our community members think about BeyondSpring and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for BeyondSpring (NASDAQ:BYSI) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings|
|Consensus Rating:||Buy (Score: 3.00)|
|Consensus Price Target: ||$54.00 (53.19% upside)|
Consensus Price Target History for BeyondSpring (NASDAQ:BYSI)
Analysts' Ratings History for BeyondSpring (NASDAQ:BYSI)
(Data available from 11/19/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|10/27/2017||Maxim Group||Reiterated Rating||Buy||$52.00||N/A|
|10/26/2017||HC Wainwright||Set Price Target||Buy||$60.00||N/A|
|7/14/2017||Rodman & Renshaw||Boost Price Target||Buy -> Buy||$43.00 -> $50.00||Medium|
Earnings History and Estimates Chart for BeyondSpring (NASDAQ:BYSI)
Earnings History by Quarter for BeyondSpring (NASDAQ BYSI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/27/2018|| || || || || || || || |
Earnings Estimates for BeyondSpring (NASDAQ:BYSI)
Current Year EPS Consensus Estimate: $-4.41 EPS
Next Year EPS Consensus Estimate: $-4.53 EPS
Dividend History for BeyondSpring (NASDAQ:BYSI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for BeyondSpring (NASDAQ BYSI)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for BeyondSpring (NASDAQ BYSI)
BeyondSpring (NASDAQ BYSI) Chart for Sunday, November, 19, 2017